Advanced Solid Tumor, Lymphoma
Conditions
Keywords
endometrial, prostate, breast, gastric, cervical, ovarian, neuroendocrine cancers, soft-tissue sarcoma, squamous cell NSCLC, renal cell carcinoma, non-Hodgkin lymphoma
Brief summary
DS-3078a will be evaluated as a single agent in subjects with advanced solid tumor malignancies or lymphomas refractory to standard treatment or for which no standard treatment is available.
Detailed description
This is a Phase 1, open-label study of DS-3078a to assess safety and tolerability, identify the maximum tolerated dose (MTD) and tentative recommended phase 2 dose (RP2D), and assess pharmacokinetic and pharmacodynamic properties in subjects with advanced solid tumor malignancies or lymphomas. The study will include 2 parts: Dose Escalation and Dose Expansion.
Interventions
DRUGDS-3078a
DS-3078a will be administered as oral capsules once daily and will be supplied in 5, 20, 50, and 150 mg capsules.
Sponsors
Daiichi Sankyo
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* A pathologically or cytologically documented advanced solid tumor or lymphoma that has relapsed from or is refractory to standard treatment or for which no standard treatment is available. * Men or women \>=18 years old. * Eastern Cooperative Oncology Group (ECOG) performance status =\<1 * Have adequate bone marrow function, defined as: * Platelet count \>=100 x 10\^9/L for solid tumors and \>=75 x 10\^9/L for lymphomas, * Hemoglobin level \>=9.0 g/dL, and ANC \>=1.5 x 10\^9/L for solid tumors and \>=1.0 x 10\^9/L for lymphomas. * Have adequate renal function, defined as: Creatinine clearance \>=60 mL/min, or creatinine =\<1.5 x ULN. * Have adequate hepatic function, defined as: * AST/ALT levels =\<3 x ULN (=\<5 x ULN if liver metastases are present) and * Bilirubin =\<1.5 x ULN. * Have adequate blood clotting function, defined as prothrombin time and activated partial thromboplastin time =\<1.5 x ULN. * Subjects must be fully informed about their illness and the investigational nature of the study protocol (including foreseeable risks and possible side effects) and must sign and date an Institutional Review Board/Ethics Committee-approved informed consent form (including Health Insurance Portability and Accountability Act authorization, if applicable) before performance of any study specific procedures or tests. For Part 2 * A pathologically or cytologically documented advanced solid tumor or non-Hodgkin lymphoma, with measurable disease based on RECIST 1.1 or revised IWG criteria, that is refractory to standard treatment. The solid tumor types that will be included in the study are of the following kinds in which the mTOR signaling is frequently activated: endometrial, prostate, breast, gastric, cervical,ovarian, or neuroendocrine cancers, soft-tissue sarcoma, squamous cell NSCLC,renal cell carcinoma or other tumor types approved by the Sponsor. * Agree to undergo pre- and post-treatment tumor biopsies.
Exclusion criteria
* History of primary central nervous system malignancies * Gastrointestinal diseases that could affect the absorption of DS-3078a in the opinion of the Investigator * Subjects with a fasting glucose \>126 mg/dL (\>7 mmol/L) * History of diabetes mellitus (type 1 or 2) or glycosylated hemoglobin \>7.0% at screening * Positive test for hepatitis B surface antigen or hepatitis C antibody * Recipient of live vaccine within 1 month of or during study drug treatment * Use of chronic systemic corticosteroids (use of nasal or inhaled steroids is permitted) * Subjects requiring daily supplemental oxygen * Recipient of an allogenic stem cell or bone marrow transplant * Presence of a concomitant medical condition that would increase the risk of toxicity, in the opinion of the Investigator or Sponsor * Clinically active brain metastases, defined as untreated and symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms. * Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to NCI-CTCAE v4 grade =\<1 or baseline. * Systemic treatment with anticancer therapy, antibody-based therapy, retinoid therapy, or hormonal therapy within 3 weeks before study drug treatment; or treatment with nitrosoureas or mitomycin C within 6 weeks before study drug treatment; or treatment with small-molecule targeted agents within 2 weeks or 5 half-lives before study drug treatment, whichever is longer. * Therapeutic radiation or major surgery within 4 weeks before study drug treatment or palliative radiation therapy within 2 weeks before study drug treatment * Participation in a clinical study within 3 weeks (2 weeks or 5 half-lives, whichever is longer, for small-molecule targeted agents) before study drug treatment, or current participation in other investigational procedures * Concomitant treatment with strong inhibitors or inducers of cytochrome P450 3A4 and P glycoprotein * Less than 1 week since using systemically acting drugs that increase gastric pH, such as H2-blockers and proton pump inhibitors. Antacids should be avoided within 48 hours of the first dose of DS 3078a * Prolongation of corrected QT interval by Fridericia's method (QTcF) at rest, where the mean QTcF interval is \>450 msec based on triplicate electrocardiogram (ECG) * Pregnant or breastfeeding * Substance abuse or medical, psychological, or social conditions that, in the opinion of the Investigator, may interfere with the subject's participation in the clinical study or evaluation of the clinical study results For Part 2 * Subjects who have had prior treatment with an mTOR catalytic site inhibitor or dual PI3K/mTOR inhibitor (including, but not limited to, OSI-027, INK128, ADZ8055,AZD2014, WYE12513, PP242, BEZ-235, DS-7423, XL765, GDC-0980, SF1126, GSK2126458, PF4691502, and PF05212384) will be disqualified from entering the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum tolerated dose | 3 years | To determine the maximum tolerated dose (MTD) and tentative recommended Phase 2 dose (RP2D) of DS 3078a |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| effect on glucose metabolism | 3 years | determine the effect of DS-3078a on glucose metabolism by measuring serum glucose and C peptide |
| assess pharmacodynamic effects tumor glucose uptake | 3 years | assess the pharmacodynamic effects of DS 3078a by determining tumor glucose uptake using (18F) fluorodeoxyglucose positron emission tomography (FDG-PET) |
| assess tumor response | 3 years | assess tumor response to DS-3078a in subjects with advanced non-Hodgkin lymphomas or advanced solid tumor types in which the mammalian target of rapamycin (mTOR) signaling pathway is frequently activated |
| determine the Cmax profile of DS 3078a | 3 years | determine the Cmax (maximum concentration) of DS-3078a administered under fed and unfed conditions |
| determine the AUC of DS 3078a | 3 years | determine the Area under the concentration versus time curve (AUC) of DS-3078a administered under fed and unfed conditions |
| determine the Tmax of DS 3078a | 3 years | determine the time of maximum concentyration (Tmax) of DS-3078a administered under fed and unfed conditions |
| determine the terminal half-life of DS 3078a | 3 years | determine the terminal half-life (T1/2) of DS-3078a administered under fed and unfed conditions |
| assess pharmacodynamic effects v-akt murine thymoma viral oncogene | 3 years | assess the pharmacodynamic effects of DS 3078a by measuring v-akt murine thymoma viral oncogene homolog 1 (Akt) phosphorylation in platelet rich plasma (PRP) |
Countries
United States
Outcome results
None listed